Cesca Therapeutics

Cesca Therapeutics is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. We focus in three target markets to serve patients, physicians and partners: •Cellular Therapeutics •Medical/Diagnostic Device Development and Commercialization •Cell Manufacturing and Banking Therapies: Cesca’s lead therapeutic technology platform, SurgWerks® (an intraoperative rapid system for harvesting, selection/purification, testing, and delivering a therapeutic dose of autologous bone marrow derived or peripheral blood derived cells and proteins), is currently in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries. Medical and Diagnostic Devices: Cesca designs, manufactures and sells advanced devices created specifically for the regenerative medicine bioprocessing market. This market includes biologic collection, transport, processing/washing, characterization/analysis, and cryopreservation. We view the regenerative medicine bioprocessing market as essential to the success of clinical trials through the control of quality of small and large scale cellular manufacturing in three distinct markets (below). Cesca provides an indication-specific device/protocol program called “Cell Werks™” for select applications in the following three markets: •Umbilical Cord Blood Banking •Bone Marrow Transplantation •RegenMed Bio-Process (Clinical/Commercialization Stage Regen Med Companies)
Company Growth (employees)
Type
Public
HQ
Rancho Cordova, US
Founded
1986
Size (employees)
95 (est)
Cesca Therapeutics was founded in 1986 and is headquartered in Rancho Cordova, US

Cesca Therapeutics Office Locations

Cesca Therapeutics has offices in Rancho Cordova and Gurgaon
Gurgaon, IN (HQ)
857 Udyog Vihar Phase V
Rancho Cordova, US (HQ)
2711 Citrus Rd

Cesca Therapeutics Data and Metrics

Cesca Therapeutics Financial Metrics

Cesca Therapeutics's revenue was reported to be $3.3 m in Q3, 2017
USD

Revenue (Q3, 2017)

3.3 m

Gross profit (Q3, 2017)

1.4 m

Gross profit margin (Q3, 2017), %

42%

Net income (Q3, 2017)

(2.1 m)

EBIT (Q3, 2017)

(2.1 m)

Market capitalization (21-Jul-2017)

35.2 m

Cash (31-Mar-2017)

3.8 m
Cesca Therapeutics's current market capitalization is $35.2 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

16 m16 m11.9 m

Revenue growth, %

0%(26%)

Cost of goods sold

10.1 m11.3 m9.2 m

Gross profit

5.9 m4.7 m2.7 m

Gross profit Margin, %

37%30%23%

Sales and marketing expense

3 m3 m2.1 m

R&D expense

3.5 m5.9 m3.2 m

General and administrative expense

8.5 m10.7 m8.2 m

Operating expense total

14.9 m19.6 m13.6 m

EBIT

(9 m)(14.9 m)(10.9 m)

EBIT margin, %

(57%)(93%)(91%)

Interest expense

(1.9 m)

Interest income

6 k

Net Income

(8.6 m)(14.9 m)(18.6 m)
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Revenue

3.7 m4.6 m4 m2.8 m3.3 m2.8 m3.8 m4 m3.3 m

Cost of goods sold

2.5 m3.1 m2.9 m2.5 m2.3 m2.4 m2.4 m2.5 m1.9 m

Gross profit

1.2 m1.5 m1.1 m367 k1 m408 k1.4 m1.6 m1.4 m

Gross profit Margin, %

32%33%28%13%31%14%37%39%42%

Sales and marketing expense

808 k720 k787 k632 k527 k537 k481 k294 k335 k

R&D expense

1.5 m1.5 m1.7 m1.1 m646 k708 k670 k694 k567 k

General and administrative expense

2.2 m3.6 m3.5 m2.6 m1.8 m1.9 m2.2 m4.1 m2.6 m

Operating expense total

4.5 m5.9 m6 m4.3 m3 m3.1 m3.3 m5.1 m3.5 m

EBIT

(3.3 m)(4.4 m)(4.8 m)(3.9 m)(2 m)(2.7 m)(1.9 m)(3.6 m)(2.1 m)

EBIT margin, %

(90%)(94%)(120%)(139%)(60%)(97%)(52%)(89%)(65%)

Interest expense

(10.5 m)(2 k)(19 k)

Interest income

(9 k)(18 k)

Net Income

(3.3 m)(4.4 m)(4.8 m)(3.4 m)(624 k)(10.9 m)(22.4 m)(3.4 m)(2.1 m)
USDFY, 2014FY, 2015FY, 2016

Cash

14.8 m3.4 m5.8 m

Accounts Receivable

6.2 k

Inventories

524 m

Current Assets

25.3 m13.3 m12.8 m

Goodwill

13.3 m13.2 m13.2 m

Total Assets

62.9 m50.8 m49.9 m

Accounts Payable

184.9 k2.6 m

Current Liabilities

6.4 m7.9 m5.5 m

Total Liabilities

17.6 m

Retained Earnings

(122.8 m)(137.7 m)(156.3 m)

Total Equity

48.7 m34.9 m32.3 m

Financial Leverage

1.3 x1.5 x1.5 x
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Cash

10.7 m8.4 m4.8 m6.6 m2.9 m7.2 m5.6 m4.9 m3.8 m

Inventories

5.9 m5.2 m5 m4 m4 m3.5 m

Current Assets

21.5 m18.4 m15.7 m14.3 m10.7 m15.1 m12.2 m10.9 m10.6 m

Goodwill

13.3 m13.2 m13.2 m13.2 m13.2 m13.2 m13.2 m13.2 m13.2 m

Total Assets

59.2 m56 m53.4 m51.9 m48.2 m52.4 m49.2 m47.9 m46.8 m

Accounts Payable

3 m3.2 m4.7 m5.7 m4.4 m3.3 m1.8 m2.1 m1.9 m

Current Liabilities

5.7 m6.6 m8.4 m8.9 m7.4 m5.9 m3.9 m5.4 m4.7 m

Retained Earnings

(126.1 m)(130.5 m)(135.3 m)(141.1 m)(141.7 m)(152.6 m)(178.7 m)(182.1 m)(184.2 m)

Total Equity

45.6 m41.6 m37 m32.3 m32.2 m35.8 m36.3 m33.7 m31.8 m

Financial Leverage

1.3 x1.3 x1.4 x1.6 x1.5 x1.5 x1.4 x1.4 x1.5 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(8.6 m)(14.9 m)(18.6 m)

Depreciation and Amortization

993 k1.4 m1.2 m

Accounts Receivable

(2.1 k)(487)2 m

Inventories

6.4 k42.1 k

Accounts Payable

(2.4 m)

Cash From Operating Activities

(7.8 m)

Capital Expenditures

(402 k)(587 k)(710 k)

Cash From Investing Activities

(51 k)(587 k)(710 k)

Cash From Financing Activities

15.8 m(189 k)12.8 m

Free Cash Flow

(8.2 m)
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Net Income

(3.3 m)(4.4 m)(4.8 m)(3.4 m)(624 k)(10.9 m)(22.4 m)(3.4 m)(2.1 m)

Inventories

5.9 m5.2 m5 m4 m4 m3.5 m

Accounts Payable

3 m3.2 m4.7 m5.7 m4.4 m3.3 m1.8 m2.1 m1.9 m
USDY, 2017

Revenue/Employee

34.2 k

Financial Leverage

1.5 x

Cesca Therapeutics Operating Metrics

FY, 2016

Patents Issued

25

Cesca Therapeutics Market Value History

Cesca Therapeutics Online and Social Media Presence

Cesca Therapeutics Company Life and Culture

You may also be interested in